GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DICE Therapeutics Inc (NAS:DICE) » Definitions » Book Value per Share

DICE Therapeutics (DICE Therapeutics) Book Value per Share : $10.86 (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is DICE Therapeutics Book Value per Share?

DICE Therapeutics's book value per share for the quarter that ended in Jun. 2023 was $10.86.

During the past 12 months, DICE Therapeutics's average Book Value Per Share Growth Rate was 49.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

DICE Therapeutics's current price is $47.55. Its book value per share for the quarter that ended in Jun. 2023 was $10.86. Hence, today's PB Ratio of DICE Therapeutics is 4.38.

During the past 4 years, the highest P/B Ratio of DICE Therapeutics was 6.16. The lowest was 1.78. And the median was 3.47.


DICE Therapeutics Book Value per Share Historical Data

The historical data trend for DICE Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DICE Therapeutics Book Value per Share Chart

DICE Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Book Value per Share
-1.28 -2.29 8.19 11.89

DICE Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.27 6.84 11.89 11.46 10.86

Competitive Comparison of DICE Therapeutics's Book Value per Share

For the Biotechnology subindustry, DICE Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DICE Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DICE Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where DICE Therapeutics's PB Ratio falls into.



DICE Therapeutics Book Value per Share Calculation

DICE Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(566.99-0.00)/47.71
=11.88

DICE Therapeutics's Book Value Per Share for the quarter that ended in Jun. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(519.06-0.00)/47.79
=10.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


DICE Therapeutics  (NAS:DICE) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


DICE Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of DICE Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


DICE Therapeutics (DICE Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
400 East Jamie Court, Suite 300, South San Francisco, CA, USA, 94080
DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.
Executives
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
John R. Jacobsen officer: CSO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Scott M. Robertson officer: CFO & CBO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Lu Timothy officer: CMO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Kevin Judice director, officer: CEO 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Lisa Bowers director C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Mittie Doyle director C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Michael P. Rubin 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Shaan-chirag C Gandhi director NORTHPOND VENTURES, 7500 OLD GEORGETOWN ROAD, BETHESDA MD 20814
Northpond Ventures Ii, Lp 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Stephen Zachary director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902